Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.

Cerevel Therapeutics (CERE) Earnings Date, Estimates & Call Transcripts

Skip Charts & View Estimated and Actual Earnings Data

CERE Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

CERE Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Cerevel Therapeutics Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20241($0.67)($0.67)($0.67)
Q2 20241($0.63)($0.63)($0.63)
Q3 20241($0.67)($0.67)($0.67)
Q4 20241($0.69)($0.69)($0.69)
FY 20244($2.66)($2.66)($2.66)

Cerevel Therapeutics Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueLinks
5/8/2024Q1 2024($0.61)($0.73)($0.12)($0.73)--  
2/27/2024Q4 2023-($0.76)($0.76)($0.76)--  
11/1/2023Q3 2023($0.63)($0.61)+$0.02($0.61)--        
8/2/2023Q2 2023($0.65)($0.63)+$0.02($0.63)--        
5/3/2023Q1 2023($0.67)($0.67)-($0.67)--        
2/22/2023Q4 2022($0.64)($0.59)+$0.05($0.59)--    
11/8/2022Q3 2022($0.62)($0.66)($0.04)($0.66)--    
8/1/2022Q2 2022($0.48)($0.62)($0.14)($0.61)--      
5/10/2022Q1 2022($0.44)($0.46)($0.02)($0.46)--        
3/1/2022Q4 2021($0.41)($0.40)+$0.01($0.40)--        
11/10/2021Q3 2021($0.40)($0.43)($0.03)($0.43)--        
8/11/2021Q2 2021($0.41)($0.42)($0.01)($0.42)--        
5/16/2021Q1 2021($0.41)($0.40)+$0.01($0.40)--    
3/24/2021Q4 2020($0.37)($0.27)+$0.10($0.27)--    
11/16/2020Q3 2020-($4.83)($4.83)($4.17)--  

Cerevel Therapeutics Earnings - Frequently Asked Questions

How much profit does Cerevel Therapeutics generate each year?

Cerevel Therapeutics (NASDAQ:CERE) has a recorded net income of -$432.84 million. CERE has generated -$2.73 earnings per share over the last four quarters.

What is Cerevel Therapeutics's EPS forecast for next year?

Cerevel Therapeutics's earnings are expected to decrease from ($2.59) per share to ($2.84) per share in the next year.


More Earnings Resources from MarketBeat


This page (NASDAQ:CERE) was last updated on 10/5/2024 by MarketBeat.com Staff
From Our Partners